Conference Coverage

VIDEO: Dr. Walter M. Stadler gives take-home messages from ASCO 2015 GU sessions


 

AT THE 2015 ASCO ANNUAL MEETING

References

CHICAGO – Dr. Walter M. Stadler provides his take on ASCO 2015 presentations and discussions around genitourinary research, including practice-changing results on the use of chemotherapy for treating prostate cancer and the timing of androgen suppression. He also addresses the disappointing results for using precision medicine to treat bladder cancer versus the encouraging results from immunotherapy for both bladder and renal cell cancer. Dr. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago. He had no financial disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

lnikolaides@frontlinemedcom.com

On Twitter @nikolaideslaura

Recommended Reading

AACR: Biomarker of response to olaparib found
MDedge Hematology and Oncology
Androgen deprivation linked to cognitive impairment
MDedge Hematology and Oncology
Symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment
MDedge Hematology and Oncology
Significant response to lacosamide in a patient with severe chemotherapy-induced peripheral neuropathy
MDedge Hematology and Oncology
ASCO: Upfront chemo prolongs life in men with advanced, hormone-naive prostate cancer
MDedge Hematology and Oncology
AUA: Very low-risk prostate cancers cause few deaths over 15 years
MDedge Hematology and Oncology
ASCO 2015: Dr. Walter M. Stadler gives his top picks in genitourinary research
MDedge Hematology and Oncology
Additive radiotherapy’s advantages outweigh QOL disadvantages
MDedge Hematology and Oncology
VIDEO: Genomic biomarker predicts pembrolizumab response
MDedge Hematology and Oncology
VIDEO: More aggressive treatment with docetaxel boosts survival in prostate cancer
MDedge Hematology and Oncology